We look forward to presenting preclinical data for our potentially differentiated HER3 ADC, EO-1022, in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. EO-1022 leverages advanced site-specific conjugation ADC technology and is being developed for the treatment of HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer. Read the full release here: investors.elevationoncology.… #ELEV #ADC #gastriccancer #AACR25

In March, our management will participate in fireside chats at two healthcare conferences. Live webcast and replay will be available on our website: investors.elevationoncology.… Full release at: investors.elevationoncology.… #ELEV #stomachcancer

As we enter 2025, we are proud to accelerate our mission of developing best-in-class ADCs and addressing significant unmet needs. With EO-3021, our differentiated Claudin 18.2 ADC, we believe we have a unique opportunity to redefine the standard of care for the early lines treatment of advanced gastric/GEJ cancer. Looking ahead, we anticipate sharing additional clinical data from our Phase 1 study monotherapy cohort in 1H 2025. Patient dosing is ongoing in the combination portion of this study. Stay tuned for more updates! Read our latest press release here: investors.elevationoncology.… #gastriccancer #ELEV

We are pleased to announce the expansion of our ADC pipeline with EO-1022, a differentiated HER3 ADC leveraging the latest in linker-payload technology and MMAE payload. investors.elevationoncology.…

Next week, our CEO, Joseph Ferra, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York. $ELEV Watch live webcast or replay later on our website: investors.elevationoncology.… Full release: investors.elevationoncology.…

This November, we come together to raise awareness of gastric cancer. Join us in supporting research and standing with those impacted by gastric cancer. Together, we can make a difference. #GastricCancerAwareness #StomachCancer #ELEV

We are excited to share new insights on our EO-3021 program at ESMO Immuno-Oncology 2024, where we’ll be presenting preclinical data of EO-3021, a differentiated, anti-Claudin 18.2 ADC, in combination with VEGFR2 or PD-1 inhibitors. cslide.ctimeetingtech.com/im… #ESMOIO $ELEV

We are excited to welcome Emiliana Fields to team Elevation, where she will take on the role of Senior Director, Quality. $ELEV Learn more about our team on the website: elevationoncology.com/about-…

We are excited to welcome Alex Chin to team Elevation, where he will take on the role of Accounts Payable Staff Accountant. $ELEV Learn more about our team on the website: elevationoncology.com/about-…

$ELEV announced that the @US_FDA granted Fast Track Designation to EO-302, a differentiated antibody drug conjugate (ADC), for treatment of gastric and gastroesophageal junction cancer expressing Claudin 18.2 that has progressed on or after prior therapy. investors.elevationoncology.…

Next week, our CEO, Joseph Ferra, will participate in the fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York. Watch live webcast or replay later on our website: investors.elevationoncology.… Full release: investors.elevationoncology.…

$ELEV reports 2Q 2024 financial results and highlights recent business achievements. Full release at investors.elevationoncology.…

$ELEV today announced promising initial data from the dose escalation portion of the ongoing Phase 1 clinical trial of EO-3021 in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2. Full release at investors.elevationoncology.…

$ELEV CEO Joe Ferra spoke with @KarenJagoda of the Empowered Patient Podcast to discuss the use of Antibody Drug Conjugates (ADCs) targeting Claudin 18.2 to treat gastric #cancer, ongoing #clinicaltrials and the future of ADCs in #oncology. empoweredpatientradio.com/an…

We are excited to welcome Dr. Henry Koon to team Elevation, where he will take on the role of Vice President, Clinical Development. $ELEV Learn more about our team on the website: elevationoncology.com/about-…

Happy 4th of July from team Elevation!

$ELEV today announced plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Full release at prnewswire.com/news-releases…

This Juneteenth, Elevation joins in recognizing freedom, resilience, and the enduring spirit of Black Americans. We stand by equality and freedom for all, committed to building a more inclusive future. #Juneteenth

At Elevation, we believe in equal rights to life, freedom, and happiness, regardless of sexual orientation or gender identity. We celebrate the LGBTQIA community and equality for all. #PrideMonth #Proud #Equality